STEREOTYPIC NEUTRALIZING VH CLONOTYPES AGAINST SARS-COV-2 RBD IN COVID-19 PATIENTS AND THE HEALTHY POPULATION

METHODS FOR TREATMENT USING CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN

PROTEASE CLEAVABLE BISPECIFIC ANTIBODIES AND USES THEREOF

ENGINEERED FC

Engineered IGA antibodies and methods of use

Bispecific antibody which binds to CD40 and EpCAM

HOMODIMERIC BISPECIFIC ANTIBODY, PREPARATION METHOD THEREFOR AND USE THEREOF

Antibodies against SARS-CoV-2 and methods of using the same

ANTI-RSPO3 ANTIBODIES AND METHODS OF USE

Methods of treatment of muscular dystrophy with ALK4:ActRIIB heteromultimers

METHODS OF PRODUCING MULTIMERIC PROTEINS IN EUKARYOTIC HOST CELLS

Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof

NON-HUMAN ANIMALS THAT SELECT FOR LIGHT CHAIN VARIABLE REGIONS THAT BIND ANTIGEN

Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof

Fc binding fragments comprising an OX40 antigen-binding site

IL10 agonists and methods of use thereof

MODULATION OF ANTIGEN IMMUNOGENICITY BY DELETING EPITOPES RECOGNIZED BY NKT CELLS

CONTORSBODY - A SINGLE CHAIN TARGET BINDER

Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors

Engineered antibody Fc variants for enhanced serum half life

Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use

ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE

Bispecific 2+1 contorsbodies

BISPECIFIC ANTIBODIES AGAINST HER2

Anti-DR5 antibodies and methods of use thereof

Fusion protein comprising IDS and use thereof

HEAVY CHAIN ONLY ANTIBODIES TO ANG-2

ANTIBODIES AND CONJUGATES THEREOF

ANTIBODY FORMULATION

COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS

Multispecific antibodies against CD40 and CD137

Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs

MULTISPECIFIC ANTIBODIES

Antibody molecules

MULTI-SPECIFIC WNT SURROGATE MOLECULES AND USES THEREOF

POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS

COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC-ANTIGEN BINDING DOMAIN CONSTRUCTS

Antibody molecule-drug conjugates and uses thereof

STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAIN

Fc binding fragments comprising a CD137 antigen-binding site

DUAL TARGETING ANTIGEN BINDING MOLECULE

Fc variants with altered binding to FcRn

COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38

Variable regions for NKp46 binding proteins

Methods of use of CD24 for the prevention and treatment of leukemia relapse

Antibodies against SARS-CoV-2 and methods of using the same

Universal T cells and the method of use thereof

FC-REGION VARIANTS WITH MODIFIED FCRN- AND PROTEIN A-BINDING PROPERTIES

MULTISPECIFIC MOLECULES THAT BIND TO MYELOPROLIFERATIVE LEUKEMIA (MPL) PROTEIN AND USES THEREOF

COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS

Anti-VLA-4 antibodies having reduced effector function

METHODS OF GLYCOPROTEIN ANALYSIS

CYTOTOXICITY-INDUCING THERAPEUTIC AGENT

Anti-lambda myeloma antigen (LMA) binding proteins to treat LMA-expressing cancer and autoimmune disorders

DIMERIC PROTEIN WITH TRIPLE MUTATIONS

Multi-specific molecules

Compositions and methods related to engineered Fc constructs

CH3 DOMAIN EPITOPE TAGS

Proteins specific for BAFF and B7RP1 and uses thereof

LAG-3-binding molecules and methods of use thereof

IgG1 FC monomer and application thereof

MULTISPECIFIC MOLECULES TARGETING CLL-1

Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation

Methods of using bispecific antigen-binding constructs targeting HER2

ANTIBODY HALF-MOLECULE, AND METHOD FOR INHIBITING HOMODIMER FORMATION OF ANTIBODY HALF-MOLECULE

TRIVALENT TRISPECIFIC ANTIBODY CONSTRUCTS

Binding proteins to the human thrombin receptor, PAR4

IN VITRO TRANSCYTOSIS ASSAY

Production of T cell retargeting hetero-dimeric immunoglobulins

NOVEL ANTIBODY FORMAT

CS1 targeted chimeric antigen receptor-modified T cells

Anti-variant Fc-region antibodies and method of use

Antibody variants and uses thereof

ANTIBODY-MODIFIED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELL AND USES THEREOF

ANTIBODY VARIANTS HAVING MODIFICATIONS IN THE CONSTANT REGION

Variant CD3-binding domains and their use in combination therapies for the treatment of disease

Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function

ANTIBODIES AND USES THEREOF

COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO PD-L1

COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF

Human antibody and fragments thereof for use in the treatment of gastric cancer (GC) and other types of tumours expressing the MICA protein (MHC class I chain-related protein A gene)

FC binding fragments comprising a PD-L1 antigen-binding site

CD19 binding molecules and uses thereof

Production of engineered T-cells by sleeping beauty transposon coupled with methotrexate selection

METHOD FOR THE GENERATION OF A MULTIVALENT, MULTISPECIFIC ANTIBODY EXPRESSING CELLS BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION

HETERODIMERIC PROTEINS

TRANSFERRIN RECEPTOR-BINDING POLYPEPTIDES AND USES THEREOF

Bispecific antibody construct directed to MUC17 and CD3

Engineered IGA antibodies and methods of use

PROXIMITY INDUCED SITE-SPECIFIC ANTIBODY CONJUGATION

Engineered IgA antibodies and methods of use

TRIFAB-CONTORSBODY

COMPOSITION OF BISPECIFIC ANTIBODIES AND METHOD OF USE THEREOF

Tau-binding antibodies

RNAi constructs for inhibiting ASGR1 expression and methods of use thereof

Heterodimeric antibodies that bind CD3 and tumor antigens

Selective sulfonation of benzodiazepine derivatives

Autoimmune suppressor and application thereof

ANTIBODY-INTERFERON FUSION PROTEINS FOR ENHANCING ADOPTIVE T CELL THERAPIES FOR THE TREATMENT OF CANCER

Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide

Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide

Methods and means for the production of Ig-like molecules

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

Anti-BACE1 antibodies and methods of use thereof

PSMA and CD3 Bispecific T Cell Engaging Antibody Constructs

Constructs having a SIRP-alpha domain or variant thereof

CONJUGATED COMPOUNDS COMPRISING CYSTEINE-ENGINEERED ANTIBODIES

Vaccine molecules

Trispecific and/or trivalent binding proteins

Multi-specific ligand binders

STABLE IgG4 ANTIBODIES

MEDITOPE-ENABLED T CELLS

IgG bispecific antibodies and processes for preparation

ANTIBODIES BINDING TO GPRC5D

VARIANT DOMAINS FOR MULTIMERIZING PROTEINS AND SEPARATION THEREOF

GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS OF MAKING AND USES THEREOF

Materials and methods for improved single chain variable fragments

Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof

Multi-Specific Molecules

POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS

Compositions comprising cyclic peptides derived from an A-beta peptide

Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof

Guidance and Navigation Control proteins and method of making and using thereof

Serpin fusion polypeptides and methods of use thereof

ANTIGEN BINDING PROTEINS TO ONCOSTATIN M (OSM)

Recombinant Cell Surface Capture Proteins

BISPECIFIC ANTIBODIES TO TNF-ALPHA AND IL-1BETA AND USES THEREOF

Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof

Methods of treating neutorpenia using G-CSF protein complex

METHODS OF MAKING AND USING GUIDANCE AND NAVIGATION CONTROL PROTEINS

GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES

Multivalent binding molecules

Transgene genetic tags and methods of use

Serpin fusion polypeptides and methods of use thereof

Monoclonal antibody specifically binding to human plasmalemma vesicle-associated protein PV-1, preparation and use thereof

Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof

Genetic engineering of non-human animals for the production of chimeric antibodies

GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES

Genetic engineering of non-human animals for the production of chimeric antibodies

Bispecific antibody for ICOS and PD-L1

FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME

Trispecific binding proteins, methods, and uses thereof

IL-21 (heterodimeric Fc-fused IL-21) fused to immunoglobulin heavy chain constant region heterodimer (heterodimeric Fc), and pharmaceutical composition comprising same

Method for generating multispecific antibodies from monospecific antibodies

HUMAN MONOCLONAL ANTI-PD-L1 ANTIBODIES AND METHODS OF USE

MULTISPECIFIC MOLECULES COMPRISING A NON-IMMUNOGLOBULIN HETERODIMERIZATION DOMAIN AND USES THEREOF

Genetic engineering of non-human animals for the production of chimeric antibodies

Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137

Multispecific antibodies that target HIV GP120 and CD3

Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors

High concentration anti-C5 antibody formulations

Compositions for increasing half-life of a therapeutic agent in canines and methods of use

BISPECIFIC ANTIBODIES COMPRISING AN ANTIGEN-BINDING SITE BINDING TO LAG3

NOVEL TNF FAMILY LIGAND TRIMER-CONTAINING ANTIGEN BINDING MOLECULES

Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV PreS1 and/or PreS2, and/or s-HBsAg regions of the HBV envelope protein

Inert format

Antigen-binding molecule containing modified antibody variable region

MULTISPECIFIC ANTIGEN BINDING PROTEINS

Binding molecules that modulate a biological activity expressed by a cell

Assembly of bispecific antibodies

BISPECIFIC ANTIBODY

Multispecific binding molecules having specificity to dystroglycan and laminin-2

Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies

VISTA antigen-binding molecules

Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same

Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein

HER3 antigen-binding molecules

Heterodimeric proteins for modulating gamma delta T cells

Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen

Multivalent Antigen-Binding Proteins

Anti-CD3 antibodies and methods of use

Anti-CD3 antibodies and methods of use

ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS

Blood-Brain Barrier Shuttles Containing Antibodies Recognizing Alpha-Synuclein

Fully human antibody specifically inhibiting Connexin 26

Binding molecules directed against influenza hemagglutinin and uses thereof

Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof

Immunoglobulins and variants directed against pathogenic microbes

AFFINITY-BASED METHODS FOR USING TRANSFERRIN RECEPTOR-BINDING PROTEINS

Anti-GD2 antibody

COMPOSITIONS AND METHODS FOR MAKING AND USING BISPECIFIC ANTIBODIES

Bispecific polypeptide complexes

Bispecific CD3/CD19 polypeptide complexes

LONG ACTING PROTEIN COMPLEX HAVING AN ENHANCED EFFICIENCY

GLP-1 FUSION PROTEINS AND USES THEREOF

Cysteine engineered antigen-binding molecules

Monoclonal antibody antagonizing and inhibiting the binding of human PD-1 antigen to its ligand, preparation method therefor and application thereof

ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF

Fc-region variants with modified FcRn-binding and methods of use

Bispecific antibodies against HER2 and CD3

ANTIBODY HAVING ENHANCED ACTIVITY, AND METHOD FOR MODIFYING SAME

Heterodimeric antibody Fc-containing proteins and methods for production thereof

Multispecific binding proteins with mutant fab domains

PseudoFab-based multispecific binding proteins

Method for in vivo generation of multispecific antibodies from monospecific antibodies

Antibody variants

Anti-C5 antibody dispensing injector and method of injection

Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)

Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimer

Multispecific antibodies against CD40 and CD137

Antibodies that bind EGFR and cMET

CHIMERIC ANTIGEN RECEPTORS (CAR) TO SELECTIVELY TARGET PROTEIN COMPLEXES

ANTIBODIES AGAINST PD-L1

Homodimeric protein constructs

Constructs having a SIRP-α domain or variant thereof

Bispecific antigen binding molecule for a costimulatory TNF receptor

PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN

Bispecific T cell activating antigen binding molecules

Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation

Dual chimeric antigen receptor-t cell which can be regulated, construction method therefor and use thereof

Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use

Engineered transferrin receptor binding polypeptides

Antibodies that modulate a biological activity expressed by a cell

Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof

Compositions for increasing half-life of a therapeutic agent in canines and methods of use

Heterodimeric proteins for modulating gamma delta T cells

Multi-chain polypeptide-containing tri-specific binding molecules

Single chain VH and heavy chain antibodies

POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS

Heterodimeric antibodies that bind CD3 and CD38

Humanized or chimeric CD3 antibodies

Tri-specific binding molecules that specifically bind to multiple cancer antigens

Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies

Methods of Producing Heterodimeric Antibodies

INTERLEUKIN-2 IMMUNOCONJUGATE, A CD40 AGONIST, AND OPTIONALLY A PD-1 AXIS BINDING ANTAGONIST FOR USE IN METHODS OF TREATING CANCER

Genetic engineering of non-human animals for the production of chimeric antibodies

Genetic engineering of non-human animals for the production of chimeric antibodies

Polypeptide variants and uses thereof

MODIFIED ANTIBODY CONSTANT REGION

METHODS OF USE OF SOLUBLE CD24 FOR NEUROPROTECTION AND REMYELINATION

SPD-1 variant# FC fusion proteins

Bispecific binding proteins and uses thereof

Heterodimerizing Ig domains

Multimeric protein purity determination

CD123 binding proteins and related compositions and methods

Asymmetric multispecific antibodies

Anti-C5 antibodies having improved pharmacokinetics

MONOVALENT AND DIVALENT BINDING PROTEINS

Method for selecting polypeptide producing cells

ANTIGEN-SPECIFIC REAGENTS SPECIFIC TO ACTIVE TGF-BETA, METHODS OF PRODUCING THE SAME, AND METHODS OF USE

Selective sulfonation of benzodiazepine derivatives

MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH

Anti-CLL-1 antibodies and methods of use

Inducible monovalent antigen binding protein

Biparatopic and multiparatopic antibodies with common light chain and method of use

Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection

Compositions and methods of use for treating metabolic disorders

PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof

Anti-transferrin receptor antibodies and methods of use

Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragments

Methods and antibody compositions for tumor treatment

Compositions and methods for targeted immunomodulatory antibodies and fusion proteins

Heavy chain constant regions with reduced binding to Fc gamma receptors

NK cell engaging antibody fusion constructs

T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS

ASPGR antibodies and uses thereof

ANTIBODY HEAVY CHAIN VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR

GARP-TGF-β 1 IGG antibodies

STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAIN

Protein complex by use of a specific site of an immunoglobulin fragment for linkage

Monoclonal antibodies against c-Met

BCMA chimeric antigen receptors

Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions

Antibody variable domains and antibody constructs

COMBINATION THERAPIES COMPRISING SIRP ALPHA-BASED CHIMERIC PROTEINS

Methods of producing multispecific antibodies against CD40 and CD137

Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303)

BCMA and CD3 bispecific T cell engaging antibody constructs

Production of heterodimeric proteins

CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE

IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS

Hetero-Dimeric Immunoglobulins

Heterodimeric proteins and preparation method thereof

Modifying binding molecules to minimize pre-exisiting interactions

Methods and means for the production of ig-like molecules

Binding molecules that bind CD137 and PD-L1

PURIFICATION OF HETERO-DIMERIC IMMUNOGLOBULINS

Fc variants

MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE

C-terminal lysine conjugated immunoglobulins

Chimeric transmembrane proteins and uses thereof

Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof

NOVEL MULTI-SPECIFIC BINDING PROTEINS

THE CONTORSBODY - A SINGLE CHAIN TARGET BINDER

Bispecific checkpoint inhibitor antibodies

Combination therapy for the treatment of cancer

Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimer

Bispecific checkpoint inhibitor antibodies

Compositions comprising antigen-binding molecules

Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions

PROTEINS BINDING BCMA, NKG2D AND CD16

Nucleic acids encoding GARP-TGF-beta 1 antibodies

MONOMERIC HUMAN IGG1 FC AND BISPECIFIC ANTIBODIES

BCMA-targeting antibody and use thereof

Binding molecules directed against influenza hemagglutinin and uses thereof

TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains

Bispecific IgG antibodies as T cell engagers

POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS

Folate receptor 1 antibodies and immunoconjugates and uses thereof

Multi-Specific Molecules